Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
G.A.P. Nieuwenhuijzen, L. Heuthorst, I. Mokadem, N. Haj Mohammad, J. de Vos-Geelen, M. van Putten, Willemieke P M Dijksterhuis, H.W.M. van Laarhoven, Rob H.A. Verhoeven
Publikováno v:
Gastric Cancer, 22(6), 1263-1273. Springer, Cham
Gastric Cancer, 22(6), 1263. Springer Japan
Gastric cancer, 22(6), 1263-1273. Springer Japan
Gastric Cancer, 22, 6, pp. 1263-1273
Gastric Cancer, 22, 1263-1273
Gastric Cancer
Gastric Cancer, 22(6), 1263. Springer Japan
Gastric cancer, 22(6), 1263-1273. Springer Japan
Gastric Cancer, 22, 6, pp. 1263-1273
Gastric Cancer, 22, 1263-1273
Gastric Cancer
Background In most western European countries perioperative chemotherapy is a part of standard curative treatment for gastric cancer. Nevertheless, recurrence rates remain high after multimodality treatment. This study examines patterns of recurrence
Autor:
Ryo Takahashi, Naoki Hiki, Masato Nagino, Manabu Ohashi, Kensei Yamaguchi, Yosuke Kano, Takeshi Sano, Satoshi Ida, Koshi Kumagai, Souya Nunobe, Keisho Chin
Publikováno v:
Gastric Cancer. 22:1256-1262
Adjuvant S-1 monotherapy prolongs the survival of patients with pathological stage II or III gastric cancer undergoing D2 gastrectomy. This therapeutic regimen is standard in Japan. Unfortunately, some patients who undergo this treatment suffer from
Autor:
Hsiang Chun Chen, Xuemei Wang, Paul F. Mansfield, Naruhiko Ikoma, Christina L. Roland, Jeannelyn S. Estrella, Jaffer A. Ajani, Prajnan Das, Cong Zhu, Keith Fournier, Wayne L. Hofstetter, Janice N. Cormier, Brian D. Badgwell, Rashida Callender
Publikováno v:
Gastric Cancer. 21:1004-1013
BACKGROUND: The benefit of preoperative chemoradiation (CXRT) over preoperative chemotherapy alone (“chemotherapy” hereafter) is unknown. By analyzing the National Cancer Database (NCDB), we investigated whether preoperative CXRT improves the inc
Autor:
Kojiro Eto, Daisuke Takahari, Keisho Chin, Naoki Hiki, Yasuo Tsuda, Souya Nunobe, Yoshiaki Shoji, Kensei Yamaguchi, Manabu Ohashi, Itaru Yasufuku, Koshi Kumagai, Takeshi Sano, Yosuke Kano, Satoshi Ida
Publikováno v:
Gastric Cancer. 21:1024-1030
One-year adjuvant S-1 monotherapy following D2 gastrectomy has been the Japanese treatment standard for pathological stage II or III gastric cancer since the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) was concluded in 2007. Trial
Autor:
Naruhiko Ikoma, Keith Fournier, Mariela A. Blum, Jeannelyn S. Estrella, Wayne L. Hofstetter, Prajnan Das, Jaffer A. Ajani, Brian D. Badgwell, Paul F. Mansfield
Publikováno v:
Gastric Cancer
BACKGROUND: The American Joint Committee on Cancer (AJCC) recently released its 8th edition staging system, which created a separate staging system for gastric cancer patients who have undergone preoperative therapy (ypStage). The objective of this r
Autor:
Shinichi Sakuramoto, Hitoshi Katai, Mitsuru Sasako, Hiroshi Imamura, Koji Kitada, Masanori Terashima, Atsushi Ochiai, Issei Kurahashi, Wataru Ichikawa, Takeshi Sano
Publikováno v:
Gastric Cancer
Background Exploratory biomarker analysis was conducted to identify factors related to the outcomes of patients with stage II/III gastric cancer using data from the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer, which was a randomized control
Autor:
Byung Sik Kim, Min-Hee Ryu, Sook Ryun Park, Yoon-Koo Kang, Sun-Young Kong, Jeong Hwan Yook, Moon-Won Yoo, Jae Ho Jeong, Baek-Yeol Ryoo, Yongchel Ahn, Beom Su Kim
Publikováno v:
Gastric Cancer. 20:146-155
Oral fluoropyrimidine S-1 contains tegafur, which is metabolized to 5-fluorouracil by cytochrome P450 2A6 (CYP2A6). We here examined associations between CYP2A6 polymorphisms and treatment outcomes of adjuvant S-1 in gastric cancer patients. Patients
Autor:
Narikazu Boku, Tomoya Yokota, Nozomu Machida, Hiroya Kashiwagi, Keita Mori, Akiko Todaka, Takahiro Tsushima, Hirofumi Yasui, Akira Fukutomi, Satoshi Hamauchi, Masao Ichinose, Kentaro Yamazaki, Yusuke Onozawa, Hiroyuki Tabuse
Publikováno v:
Gastric Cancer. 19:894-901
Watering eyes is a common late adverse event associated with S-1 chemotherapy; however, the frequency and predictive factors are not known.This study included 304 consecutive gastric cancer patients treated with adjuvant S-1 monotherapy for 1 year at
Autor:
Takaki Yoshikawa, Takashi Ogata, Haruhiko Cho, Hiroshi Kuwabara, Akira Tsuburaya, Tsutomu Hayashi, Toru Aoyama, Yo Mikayama
Publikováno v:
Gastric Cancer. 16:133-139
The factors that affect the 6-month continuation of adjuvant chemotherapy with S-1 have not been fully evaluated. The objective of this retrospective study was to clarify the risk factors for 6-month continuation of S-1 adjuvant chemotherapy.The stud
Autor:
Takafumi Watanabe, Takashi Ogata, Toru Aoyama, Takaki Yoshikawa, Haruhiko Cho, Akira Tsuburaya, Tsutomu Hayashi
Publikováno v:
Gastric Cancer. 15:76-82
The safety and feasibility of administering S-1 adjuvant chemotherapy for gastric cancer has not been fully evaluated in elderly patients.This retrospective study selected patients who underwent curative D2 surgery for gastric cancer, were diagnosed